摘要
目的:探讨重组人血管内皮抑素(recombinant human endostatin,ES)联合重组人P53腺病毒(rAd/P53)对乳腺癌细胞MCF-7裸鼠移植瘤的抑制作用。方法:建立裸鼠荷人乳腺癌模型,随机分为对照组、ES组、rAd/P53组和两药联合组,分别给予相应治疗;观察肿瘤生长,免疫组化法检测肿瘤组织微血管密度(microvessel density,MVD)和血管内皮生长因子(vascu-larendothelial growth factor,VEGF)的表达。结果:各治疗组均可明显抑制移植瘤生长,ES组、rAd/P53组和联合用药组的抑瘤率分别为51.67%、48.74%和75.54%,联合用药组抑瘤作用最为显著(P<0.05)。对照组、ES组、rAd/P53组与联合用药组的移植瘤组织MVD分别为31.17±2.48、20.33±4.84、22.33±3.88及12.50±2.74,VEGF表达H评分分别为45.33±5.89、35.83±5.46、33.67±4.80及22.33±4.41,联合用药组的MVD和VEGF表达显著低于其余各组(P<0.01)。结论:重组人ES联合rAd/P53治疗可显著抑制裸鼠乳腺癌移植瘤的生长及微血管生成。
Objective： To investigate the inhibitory effect of recombinant human endostatin （ES）combined with tAd/P53 on transplanted human breast cancer cell MCF-7 in nude mice. Methods： Animal breast cancer model was established by inoculating MCF-7 cells in nude mice. The animals were randomized into control group, ES group, rAd/P53 group, and ES ＋ tAd/P53 group. The tumor growth was observed in each group and immunohistochemical method was employed to examine the microvessel density （MVD） and the expression of vascular endothelial growth factor （VEGF）. Results ： Tumor growth was significantly inhibited in all the 3 treatment groups （P 〈 0.05 ） , with the inhibitory rates being 51.67% ,48.74% and 75.54% in ES, rAd/P53, and ES ＋ tAd/P53 group, respectively. The value of MVD in control, ES , rAd/P53, and ES ＋ tAd/P53 group were 31.17 ± 2.48, 20.33 ± 4.84, 22.33 ± 3.88 and 12.50 ± 2.74, respectively; and their VEGF H-scores were 45. 33 ±5. 89, 33. 67 ± 4. 80, 40. 17 ± 4. 74 and 22. 33 ± 4.41, respectively. The MVD value and VEGF expression in the ES ＋ rAd/P53 group were significantly lower than those of the other groups （P 〈0.01 ）. Conclusion： Recombinant human endostatin combined with rAd/P53 can greatly inhibit the growth of transplanted human breast tumor in nude mice and reduce the formation of capillary.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2008年第5期470-473,共4页
Chinese Journal of Cancer Biotherapy
基金
首都医学发展科研基金联合攻关项目( No.2005-1-161)~~
